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However, the authors used a strict definition for the ‘validated
algorithm-based’ diagnosis of HS, and the sociodemographic
characteristics and comorbidities of the ‘validated algorithm-
based’ HS population were consistent with previous studies,
minimizing classification bias.
Finally, the authors should be congratulated for the
robustness of their study in terms of its design, opening a
new methodological avenue in the pharmacoepidemiology
field, where diagnostic criteria are lacking. This study
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Proper measurement of the characteristics of a disease is an
important topic in medical science. Measurements can be per-
formed to assess characteristics such as severity, symptoms,
extent or impairment. They can also be clustered in a con-
struct like health-related quality of life, often covering impair-
ment in several domains (e.g. symptoms, emotions or
functioning). Once it is clear how to measure a certain charac-
teristic and which instrument is best suited for this, the next
step is to determine how to interpret the outcome of such an
instrument.
In this issue of the British Journal of Dermatology Vakharia et al.
present the results of an interpretability study, designed to
determine severity strata for several patient-reported out-
come (PRO) measurement instruments used in atopic der-
matitis (AD): the Patient Oriented Eczema Measure (POEM),
Numerical Rating Scale (NRS)-itch, raw/mean ItchyQoL,
5-D itch and Dermatology Life Quality Index (DLQI).1 When
determining strata, measured scores are compared with
scores obtained with a single question with clearly labelled
answer categories (the ‘anchor’), chosen to represent the
desired characteristic for interpretation; in this case disease
severity.2
A difficult issue is that a ‘true’ disease severity of AD in
general does not exist. For example, it matters whether one
asks a patient or a physician to judge the disease severity.
How should it be judged? Should disease severity incorporate
only clinical signs or also symptoms, e.g. itch and pain?
Should one ask about the frequency or the intensity of these
symptoms? Or should one focus on how much they bother a
patient?3,4
The authors chose to use one broad anchor question for all
mentioned instruments: ‘Would you describe your atopic
dermatitis or eczema as mild, moderate, or severe?’ In their
validation paper of this single question, the authors conclude
that it might be an important PRO for assessing the overall
burden of disease that accounts for severity, extent, symptom
burden and quality of life impact.5
In the current study, the use of this anchor assessing
‘overall burden’ is probably the main reason why correla-
tions with severity strata of the studied measurement instru-
ments were found to be modest at best (kappa ranging from
0331 to 0499). For example, a patient indicating an overall
severe burden of AD does not necessarily have to experience
severe itching (resulting in a low score for the itch-related
instruments). Another explanation could be the lack of a
specified time frame for the anchor, while the studied
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instruments have time frames of between 7 and 14 days.
The authors justly conclude that each of the studied instru-
ments assesses different aspects of the multidimensional
impact that AD has on patients, with only partial overlap.
This means that each instrument has a potential added value,
and measurements with more than one instrument are neces-
sary. Considering this, in future interpretability studies it
would be interesting to see the use of anchor questions
specifically tailored to the dimension/domain of the studied
instrument; for example, anchor questions for the ItchyQoL
and 5-D itch should ask about the bother patients experience
because of their itch.
An interesting finding is that the strata for NRS-itch had a
stronger correlation with the anchor than strata of the
POEM. Although POEM was chosen by the Harmonizing
Outcome Measurements in Eczema (HOME) group as the
preferred core instrument to assess patient-reported symp-
toms,6 Vakharia et al. suggest considering NRS-itch as an
additional assessment.
In conclusion, when interpreting scores from patients,
regardless of the disease, one should always be aware of how
strata for interpretability were determined. The choice of
anchor is often vital for interpretability.
Acknowledgments
The author would like to acknowledge M.L.A. Schuttelaar and
R.F. Ofenloch for their critical revision of this commentary.
Conflicts of interest
None to declare.
J .A .F . OOST ERHAV EN iDDepartment of Dermatology, University
Medical Center Groningen, PO Box 30 001,
9700 RB Groningen, the Netherlands
E-mail: j.a.f.oosterhaven@umcg.nl
References
1 Vakharia PP, Chopra R, Sacotte R et al. Severity strata for five
patient-reported outcomes in adults with atopic dermatitis. Br J Der-
matol 2018; 178:925–30.
2 de Vet HCW, Terwee CB, Mokkink LB, Knol DL (eds). Measurement in
Medicine. New York: Cambridge University Press, 2011; 227–74.
3 Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema
Area and Severity Index score tells us about the severity of atopic
dermatitis: an interpretability study. Br J Dermatol 2015; 172:1353–7.
4 Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating
Patient-Oriented Eczema Measure (POEM) scores into clinical prac-
tice by suggesting severity strata derived using anchor-based meth-
ods. Br J Dermatol 2013; 169:1326–32.
5 Vakharia PP, Chopra R, Sacotte R et al. Validation of patient-reported
global severity of atopic dermatitis in adults. Allergy 2018; 73:451–8.
6 Spuls PI, Gerbens LAA, Simpson E et al. Patient-Oriented Eczema
Measure (POEM), a core instrument to measure symptoms in clini-
cal trials: a Harmonising Outcome Measures for Eczema (HOME)
statement. Br J Dermatol 2017; 176:979–84.
Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website:
Audio S1 Author audio.
Association of APOE polymorphisms with
multibacillary leprosy
DOI: 10.1111/bjd.16361
Linked Article: Wang et al. Br J Dermatol 2018; 178:931–
939.
In an article in this issue of the British Journal of Dermatology,
using integrated expression quantitative trait loci, mRNA
expression and protein interaction analysis, Wang et al.1 report
on some potential genetic associations between the human
apolipoprotein E (ApoE) gene and leprosy in Han Chinese
patients from Southwest China.
Despite new information mainly at the molecular level, the
pathogenesis of leprosy remains poorly understood. Epidemio-
logical studies have shown the importance of host genetic factors
in susceptibility to the development of leprosy and the clinical
form of the disease. Several chromosomal regions associated with
leprosy have been identified in genome-wide linkage analysis.2
The APOE gene is located in chromosome 19q13 and
encodes a member of the family of soluble apolipoproteins
with polymorphic alleles carrying homozygous and heterozy-
gous genotypes. The molecular basis of APOE single-nucleotide
polymorphisms (SNPs) is cysteine–arginine interchanges.3
APOE SNPs are the main genetic determinant of Alzheimer
disease (AD) risk: individuals carrying the e4 allele are at
increased risk of AD compared with those carrying the more
common e3 allele, whereas the e2 allele decreases the risk.3
Conversely, in patients with leprosy without dementia, the
frequency of the e4 allele was significantly higher, suggesting
that this allele is not a risk factor for dementia in elderly
patients with leprosy.4 Furthermore, histological analyses of
brain tissue of elderly patients with leprosy without dementia
showed a significantly lower frequency of deposition of
b-amyloid, the cue molecule involved in AD, than age-
matched controls without dementia.5 The results suggest that
patients with leprosy might have a low risk of AD.
Although the finding is controversial,6 antileprosy drugs
appear to reduce dementia, as shown in elderly patients with
leprosy treated with dapsone.7 Furthermore, rifampicin
inhibited the initial step of b-amyloid formation, showing
activity against the accumulation and toxicity of intracellular
b-amyloid.8
Lepromatous leprosy (LL) exhibits extensive involvement of
the skin and peripheral nerves. A typical feature of LL is the
survival and replication of Mycobacterium leprae stored within the
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